You just read:

Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting

News provided by

Regeneron Pharmaceuticals, Inc.

Nov 06, 2019, 09:00 ET